search
Back to results

Safety and Efficacy of Adding Intravenous N-acetyl Cysteine in Colon Surgeries

Primary Purpose

Systemic Inflammatory Response Syndrome

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
N Acetyl L Cysteine
dextrose 5%
Sponsored by
Ain Shams University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Systemic Inflammatory Response Syndrome

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • need for ICU admission after colonic surgery
  • requirement of total parenteral nutrition for at least 5 days due to failure of or contraindication for enteral nutrition
  • signing a written informed consent.

Exclusion Criteria:

  • patients with persistent hemodynamic instability (systolic blood pressure <80 mm Hg), renal impairment, hepatic insufficiency, severe or uncontrolled sepsis, persistent metabolic acidosis, head trauma,and heart failure
  • any sensitivity to components of L-alanyl L-glutamine (Dipeptiven®, Fresenius Kabi, Germany) or N acetyl cysteine

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    N acetylcysteine group

    placebo group

    Arm Description

    N Acetyl L Cysteine IV bolus (100 mg/kg dissolved in dextrose5%) infused over 15 minutes, followed by continuous infusion of 50mg/kg/day dissolved in dextrose 5% starting 1hr before induction of anesthesia, and continued for 48 hours after operation

    received equal volume of dextrose 5% administrated at the same rate and duration as in the study group as a placebo

    Outcomes

    Primary Outcome Measures

    assessing a change in the level of tumor necrosis factor alpha (TNF alpha) as ant-inflammatory marker reflecting n acetyl cysteine efficacy
    TNF alpha was measured using ELISA technique
    assessing a change in the level of malondialdehyde as antioxidant marker in the venous blood sample reflecting n acetyl cysteine efficacy
    malondialdehyde was measured using colorimetric method for assay

    Secondary Outcome Measures

    measuring safety of N acetyl cysteine (adverse effects)
    recording any adverse effects that may appear

    Full Information

    First Posted
    June 15, 2018
    Last Updated
    July 17, 2018
    Sponsor
    Ain Shams University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03589495
    Brief Title
    Safety and Efficacy of Adding Intravenous N-acetyl Cysteine in Colon Surgeries
    Official Title
    Safety and Efficacy of Adding Intravenous N-acetyl Cysteine to Parenteral L-alanyl L-glutamine in Hospitalized Patients Undergoing Colon Surgeries
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    July 30, 2015 (Actual)
    Primary Completion Date
    October 15, 2016 (Actual)
    Study Completion Date
    October 15, 2016 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Ain Shams University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No

    5. Study Description

    Brief Summary
    The use of antioxidant agents in the prevention or decreasing the severity of postoperative systemic inflammatory response syndrome after colonic surgeries adopted nowadays. Therefore, it is of interest to investigate safety and efficacy of administrating short term intravenous (IV) N acetyl cysteine as add on to l alany l glutamine and total parenteral nutrition on the marker of oxidative stress malondialdehyde and anti- inflammatory marker tumor necrosis factor alpha in patients undergoing colonic surgeries through a prospective, randomized, double blinded, controlled clinical trial
    Detailed Description
    A prospective, randomized, double blinded, controlled clinical trial will be carried out on 60 patients, who will admit to the critical care unit, Ain Shams hospitals, Cairo, Egypt, following colon surgeries. Before the start of the study, eligible patients were randomized using computer generated list in order to allocate participants to either Group I (n acetyl cysteine group) or Group II (control group) in an equal manner No medication will take before the surgery and only oral fluids were allowed on the day before the operation. All eligible patients underwent bowel preparation with oral 1.745 g/ 30 ml magnesium citrate, and phosphate containing enema on the day before surgery. All patients received the general anesthesia with endotracheal intubation and muscle relaxant. Data management and analysis were performed using the Statistical Package for Social Sciences (SPSS) software for Windows version 18

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Systemic Inflammatory Response Syndrome

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    60 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    N acetylcysteine group
    Arm Type
    Active Comparator
    Arm Description
    N Acetyl L Cysteine IV bolus (100 mg/kg dissolved in dextrose5%) infused over 15 minutes, followed by continuous infusion of 50mg/kg/day dissolved in dextrose 5% starting 1hr before induction of anesthesia, and continued for 48 hours after operation
    Arm Title
    placebo group
    Arm Type
    Placebo Comparator
    Arm Description
    received equal volume of dextrose 5% administrated at the same rate and duration as in the study group as a placebo
    Intervention Type
    Drug
    Intervention Name(s)
    N Acetyl L Cysteine
    Intervention Description
    100 mg/kg n acetyl cysteine dissolved in dextrose5%
    Intervention Type
    Other
    Intervention Name(s)
    dextrose 5%
    Primary Outcome Measure Information:
    Title
    assessing a change in the level of tumor necrosis factor alpha (TNF alpha) as ant-inflammatory marker reflecting n acetyl cysteine efficacy
    Description
    TNF alpha was measured using ELISA technique
    Time Frame
    Venous blood samples were obtained before surgery (baseline evaluation), and on day two after surgery for measuring changes in TNF ALPHA
    Title
    assessing a change in the level of malondialdehyde as antioxidant marker in the venous blood sample reflecting n acetyl cysteine efficacy
    Description
    malondialdehyde was measured using colorimetric method for assay
    Time Frame
    Venous blood samples were obtained before surgery (baseline evaluation), and on day two after surgery for measuring changes in malondialdehyde level
    Secondary Outcome Measure Information:
    Title
    measuring safety of N acetyl cysteine (adverse effects)
    Description
    recording any adverse effects that may appear
    Time Frame
    from the beginning of the study till the patient is discharged from the hospital(up to one week)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: need for ICU admission after colonic surgery requirement of total parenteral nutrition for at least 5 days due to failure of or contraindication for enteral nutrition signing a written informed consent. Exclusion Criteria: patients with persistent hemodynamic instability (systolic blood pressure <80 mm Hg), renal impairment, hepatic insufficiency, severe or uncontrolled sepsis, persistent metabolic acidosis, head trauma,and heart failure any sensitivity to components of L-alanyl L-glutamine (Dipeptiven®, Fresenius Kabi, Germany) or N acetyl cysteine
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    manal elhammsy, prof
    Organizational Affiliation
    Ain Shams University , faculty of pharmacy
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    All the individual participant data will be stored on the computer and will be available on request only
    IPD Sharing Time Frame
    it will be available once the trial ends, and for 3 months after publication
    IPD Sharing Access Criteria
    data will be available on request
    Citations:
    PubMed Identifier
    31381364
    Citation
    Hamamsy ME, Bondok R, Shaheen S, Eladly GH. Safety and efficacy of adding intravenous N-acetylcysteine to parenteral L-alanyl-L-glutamine in hospitalized patients undergoing surgery of the colon: a randomized controlled trial. Ann Saudi Med. 2019 Jul-Aug;39(4):251-257. doi: 10.5144/0256-4947.2019.251. Epub 2019 Aug 5.
    Results Reference
    derived

    Learn more about this trial

    Safety and Efficacy of Adding Intravenous N-acetyl Cysteine in Colon Surgeries

    We'll reach out to this number within 24 hrs